FDA
-
-
-
-
-
-
-
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Schedules First Commercial Shipment of YUTREPIA Inhalation Powder
-
-
-
-
-
-
-
Liquidia Technologies (LQDA): U.S. FDA Approves YUTREPIA Inhalation Powder for Patients with PAH and PH-ILD
-
-
-
-
-
-
-
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Liquidia Technologies (LQDA)
-
-
-
-
-
-
-
Liquidia Technologies (LQDA) Raises $67.5M from Share Sales, $32.5M Advance from HealthCare Royalty Under Current Financing Agreement
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on United Therapeutics Corp. (UTHR)
-
328,337 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

